Related Stories
Progress
For Sopharma AD this effort is another contribution to an excellent corporate governance file.
| Distribution of sales revenues by geographic region | |
|---|---|
| % | |
| Europe | 33 |
| Bulgaria | 66 |
| Other | 1 |
The contribution of sales in Bulgaria to the consolidated sales revenue in the nine months of 2020 amounted to 66%, increasing by 12% compared to thenine months of 2019. Sopharma has a 3% share on the Bulgarian pharmaceutical market in terms of value and a 10% share in terms of solid quantity - units:
- Novartis: 6.8% (3.8% in units)
- Roche: 6.8% (0.2 in units)
- Actavis: 4.3% (10% in units)
- GlaxoSmithKlein: 2.8% (2.4% in units)
- Abbvie: 3.7% (0% in units)
- Sanofi-Aventis: 2.6% (2% in units)
- Astra Zeneca: 2.9% (0.4% in units)
- Pfizer: 4% (1% in units)
- Merck: 4.3% (0.8% in units)